<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        419-212-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Imesta 500 mg/500 mg Powder For IV Infusion (1Vial)
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CILASTATIN,IMIPENEM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500,500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        34.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACS Dobfar S.p.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACS Dobfar S.p.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DH51
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&#39;IMESTA&#39; belongs to a group of medicines called carbapenem antibiotics. It kills a wide range of<br />bacteria (germs) that cause infections in various parts of the body in adults and children one year<br />of age and above.<br />&nbsp;</p><p><strong>Treatment</strong><br />Your doctor has prescribed &#39;IMESTA&#39; because you have one (or more) of the following types of<br />infection:<br />&bull; Complicated infections in the abdomen<br />&bull; Infection affecting the lungs (pneumonia)<br />&bull; Infections that you can catch during or after the delivery of your baby<br />&bull; Complicated urinary tract infections<br />&bull; Complicated skin and soft tissue infections</p><p>&#39;IMESTA&#39; may be used in the management of patients with low white blood cell counts, who<br />have fever that is suspected to be due to a bacterial infection.<br />&#39;IMESTA&#39; may be used to treat bacterial infection of the blood which might be associated with a<br />type of infection mentioned above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use &#39;IMESTA&#39;</strong><br />- If you are allergic (hypersensitive) to imipenem, cilastatin or any of the other ingredients of<br />&#39;IMESTA&#39;</p><p>- If you are allergic (hypersensitive) to other antibiotics such as penicillins, cephalosporins, or<br />carbapenems</p><p><strong>Take special care with &#39;IMESTA&#39;</strong><br />Tell your doctor about any medical condition you have or have had including:<br />- Allergies to any medicines including antibiotics (sudden life-threatening allergic reactions<br />require immediate medical treatment)<br />- Colitis or any other gastrointestinal disease kidney or urinary problems, including reduced<br />kidney function (&lsquo;IMESTA&rsquo; blood levels increase in patients with reduced kidney function.<br />Central nervous system adverse reactions may occur if the dose is not adjusted to the kidney<br />function)<br />- Any central nervous system disorders such as localized tremors or epileptic seizures (fits)<br />- Liver problems<br />You may develop a positive test (Coombs test) which indicates the presence of antibodies that<br />may destroy red blood cells. Your doctor will discuss this with you.<br />Tell your doctor if you are taking medicines called valproic acid or sodium valproate (see Using<br />other medicines below).</p><p><em>Children</em><br />&#39;IMESTA&#39; is not recommended in children less than one year of age or children with kidney<br />problems.</p><p><strong>Using other medicines</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other<br />medicines, including those obtained without a prescription.<br />Tell your doctor if you are taking ganciclovir which is used to treat some viral infections.<br />Also, tell your doctor if you are taking valproic acid or sodium valproate (used to treat epilepsy,<br />bipolar disorder, migraine, or schizophrenia) or any blood thinners such as warfarin.<br />Your doctor will decide whether you should use &#39;IMESTA&#39; in combination with these medicines.</p><p><strong>Pregnancy and breast-feeding</strong><br />It is important that you tell your doctor if you are pregnant or are planning to become pregnant<br />before receiving &#39;IMESTA&#39;. &#39;IMESTA&#39; has not been studied in pregnant women. &#39;IMESTA&#39;<br />should not be used during pregnancy unless your doctor decides the potential benefit justifies the<br />potential risk to the developing baby.<br />It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed<br />before receiving &#39;IMESTA&#39;. Small amounts of this medicine may pass into breast milk and it may<br />affect the baby. Therefore, your doctor will decide whether you should use &#39;IMESTA&#39; while<br />breast-feeding.<br />Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong></p><p>There are some side effects associated with this product (such as seeing, hearing, or feeling<br />something that is not there, dizziness, sleepiness, and a spinning sensation) that may affect some<br />patients&#39; ability to drive or operate machinery (see section 4).</p><p><strong>Important information about some of the ingredients of &#39;IMESTA&#39;</strong><br />This medicinal product contains approximately 20 mg of sodium per 500 mg dose which should<br />be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&#39;IMESTA&#39; will be prepared and given to you by a doctor or another health care professional.<br />Your doctor will decide how much &#39;IMESTA&#39; you need.<br />Adults and adolescents<br />The usual dose of &#39;IMESTA&#39; for adults and adolescents is 500 mg/500 mg every 6 hours or 1,000<br />mg/1,000 mg every 6 or 8 hours. If you have kidney problems or weigh less than 70 kg, your<br />doctor may lower your dose.<br />Children<br />The usual dose for children one year of age or older is 15/15 or 25/25 mg/kg/dose every 6 hours.<br />&#39;IMESTA&#39; is not recommended in children under one year of age and children with kidney<br />problems.<br />Method of administration<br />&#39;IMESTA&#39; is given intravenously (into a vein) over 20-30 minutes for a dose of &le;500<br />mg/500 mg or 40-60 minutes for a dose of &gt;500 mg/500 mg. The rate of infusion may<br />be slowed if you feel sick.</p><p><strong>If you use more &#39;IMESTA&#39; than you should</strong><br />Symptoms of overdose may include seizures (fits), confusion, tremors, nausea, vomiting, low<br />blood pressure and slow heart rate. If you are concerned that you may have been given too much<br />&#39;IMESTA&#39;, contact your doctor or another healthcare professional immediately.</p><p><strong>If you forget to use &#39;IMESTA&#39;</strong><br />If you are concerned that you may have missed a dose, contact your doctor or another healthcare<br />professional immediately.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, &#39;IMESTA&#39; can cause side effects, although not everybody gets them.<br />The frequency of possible side effects listed below is defined using the following convention:<br />&bull; Very common: affects more than 1 user in 10<br />&bull; Common: affects 1 to 10 users in 100<br />&bull; Uncommon: affects 1 to 10 users in 1,000<br />&bull; Rare: affects 1 to 10 users in 10,000<br />&bull; Very rare: affects less than 1 user in 10,000</p><p>&bull; Not known: frequency cannot be estimated from the available data<br />The following side-effects occur rarely, however if they do occur, while receiving or after<br />receiving &#39;IMESTA&#39;, the medicine must be stopped and your doctor contacted immediately.<br />&bull; Allergic reactions including rash, swelling of the face, lips, tongue, and/or throat (with<br />difficulty in breathing or swallowing), and/or low blood pressure<br />&bull; Skin peeling (toxic epidermal necrolysis)<br />&bull; Severe skin reactions (Stevens-Johnson syndrome and erythema multiforme)<br />&bull; Severe skin rash with loss of skin and hair (exfoliative dermatitis)<br />Other possible side effects:</p><p><strong>Common</strong><br />&bull; Nausea, vomiting, diarrhoea. Nausea and vomiting appear to occur more frequently in patients<br />with low number of white blood cells<br />&bull; Swelling and redness along a vein which is extremely tender when touched<br />&bull; Rash<br />&bull; Abnormal liver function detected by blood tests<br />&bull; Increase in some white blood cells</p><p><strong>Uncommon</strong><br />&bull; Local skin redness<br />&bull; Local pain and formation of a firm lump at the injection site<br />&bull; Skin itchiness<br />&bull; Hives<br />&bull; Fever<br />&bull; Blood disorders affecting the cell components of the blood and usually detected by blood tests<br />(symptoms may be tiredness, paleness of skin, and prolonged bruising after injury)<br />&bull; Abnormal kidney, liver and blood function detected by blood tests<br />&bull; Tremors and uncontrolled twitching of muscles<br />&bull; Seizures (fits)<br />&bull; Psychic disturbances (such as mood swings and impaired judgment)<br />&bull; Seeing, hearing or feeling something that is not there (hallucinations)<br />&bull; Confusion<br />&bull; Dizziness, sleepiness<br />&bull; Low blood pressure</p><p><strong>Rare</strong><br />&bull; Fungal infection (candidiasis)<br />&bull; Staining of the teeth and/or tongue<br />&bull; Inflammation of the colon with severe diarrhoea<br />&bull; Disturbances in taste<br />&bull; Inability of the liver to perform normal function<br />&bull; Inflammation of the liver<br />&bull; Inability of the kidney to perform normal function<br />&bull; Changes in the amount of urine, changes in urine colour<br />&bull; Disease of the brain, tingling sensation (pins and needles), localised tremor<br />&bull; Hearing loss</p><p><strong>Very rare</strong><br />&bull; Severe loss of liver function due to inflammation (fulminant hepatitis)<br />&bull; Inflammation of stomach or intestine (gastro-enteritis)<br />&bull; Inflammation of intestine with bloody diarrhoea (haemorrhagic colitis)<br />&bull; Red swollen tongue, overgrowth of the normal projections on the tongue giving it a hairy<br />appearance, heartburn, sore throat, increase in the production of saliva<br />&bull; Stomach pain<br />&bull; A spinning sensation (vertigo), headache<br />&bull; Ringing in the ears (tinnitus)<br />&bull; Pain in several joints, weakness<br />&bull; Irregular heartbeat, the heart beating forcefully or rapidly<br />&bull; Chest discomfort, difficulty breathing, abnormally fast and superficial breathing, pain in the<br />upper spine<br />&bull; Flushing, bluish discoloration of the face and lips, skin texture changes, excessive sweating<br />&bull; Itching of the vulva in women<br />&bull; Changes in the amounts of blood cells<br />&bull; Worsening of a rare disease associated with muscle weakness (aggravation of myasthenia<br />gravis)</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,<br />please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use &#39;IMESTA&#39; after the expiry date stated on the container. The expiry date refers to the<br />last day of that month.<br />Do not store above 30 &deg;C.<br />After reconstitution:<br />Diluted solutions should be used immediately. The time interval between the beginning of<br />reconstitution and the end of intravenous infusion should not exceed two hours at 30 &deg;C.<br />Do not freeze the reconstituted solution.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist<br />how to dispose of medicines no longer required. These measures will help to protect the<br />environment.<br />&nbsp;</p><p><strong>The following information is intended for medical or healthcare professionals only:<br />Each vial is for single use only.<br />Reconstitution</strong><br />Contents of each vial must be transferred to 100 ml of an appropriate infusion solution <strong>(see<br />Incompatibility and After reconstitution</strong>): 0.9% sodium chloride. In exceptional circumstances<br />where 0.9% sodium chloride cannot be used for clinical reasons, 5% glucose may be used<br />instead.</p><p>A suggested procedure is to add approximately 10 ml of the appropriate infusion solution to the<br />vial. Shake well and transfer the resulting mixture to the infusion solution container.<br />CAUTION: THE MIXTURE IS NOT FOR DIRECT INFUSION.<br />Repeat with an additional 10 ml of infusion solution to ensure complete transfer of vial contents<br />to the infusion solution. The resulting mixture should be agitated until clear.<br />The concentration of the reconstituted solution following the above procedure is approximately 5<br />mg/ml for both imipenem and cilastatin.<br />Variations of colour, from colourless to yellow, do not affect the potency of the product.</p><p><strong>Incompatibility</strong><br />This medicinal product is chemically incompatible with lactate and should not be reconstituted in<br />diluents containing lactate. However, it can be administered into an I.V. system through which a<br />lactate solution is being infused.<br />This medicinal product must not be mixed with other medicinal products except those mentioned<br />under Reconstitution.</p><p><strong>After reconstitution</strong><br />Diluted solutions should be used immediately. The time interval between the beginning of<br />reconstitution and the end of intravenous infusion should not exceed two hours 30 &deg;C.<br />Any unused product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substances are imipenem and cilastatin.<br />Each vial contains imipenem monohydrate equivalent to 500 mg imipenem and cilastatin sodium<br />equivalent to 500 mg cilastatin.<br />- The other ingredient is sodium bicarbonate 20mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                'IMESTA' is a white to light yellow powder for solution for infusion in a glass vial. Pack sizes of
1, 10 or 25 vials. Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong><br />ACS DOBFAR S.P.A<br />For<br />SPIMACO<br />Saudi Pharmaceutical Industries &amp;<br />Medical Appliance Corporation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمی إيمیستا إلى مجموعة من الأدوية تسمى المضادات الحیوية (كاربابینیم). فھو يقتل مجموعة واسعة من البكتريا (الجراثیم)</p><p dir="RTL">التي تسبب عدوى في أجزاء مختلفة من الجسم في البالغين والأطفال من عمر سنة واحدة وما فوق.</p><p dir="RTL">العلاج</p><p dir="RTL">قد وصف الطبیب إيمیستا لأن لديك واحدة (أو أكثر) من الأنواع التالیة من :</p><p dir="RTL">&bull; عدوى معقدة فی منطقة البطن</p><p dir="RTL">&bull; العدوى التی تؤثر على الرئتین (التھاب رئوي)</p><p dir="RTL">&bull; العدوى التی یمكن الإصابة بھا أثناء أو بعد الولادة</p><p dir="RTL">&bull; عدوى المسالك البولیة المعقدة</p><p dir="RTL">&bull; عدوى الجلد والأنسجة اللینة</p><p dir="RTL">يمكن أن یستخدم إيمیستا للمرضى الذين یعانون من انخفاض عدد خلايا الدم البیضاء فی الدم،</p><p dir="RTL">والذين یعانون من الحمى التی یشتبه فی أن تكون بسبب عدوى بكتیرية.</p><p dir="RTL">يمكن استخدام إيمیستا لعلاج العدوى البكتیرية فی الدم والتی قد تتزامن مع نوع من أنواع العدوى المذكورة أعلاه .</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول إيمیستا إذا:</p><p dir="RTL">- كان لديك حساسیة زائدة (فرط حساسیة) تجاھ إيمیبینیموسیلاستاتین أو أي من المكونات الأخرى لإيمیستا</p><p dir="RTL">- كان لديك حساسیة زائدة (فرط حساسیة) تجاھ المضادات الحیوية الأخرى مثل بینیسیلین أو سیفالوسبورين أو كاربابینیم</p><p dir="RTL">ینبغي توخى الحذر مع إیمیستا فى الحالات التالیة</p><p dir="RTL">أخبر طبیبك عن أي حالة طبیة لديك أو كانت لديك في السابق بما فی ذلك:</p><p dir="RTL">- الحساسیة لأية أدوية بما فی ذلك المضادات الحیوية (ردود الفعل التحسسیة المفاجئة التی قد تھدد الحیاة تتطلب معالجة طبیة فورية)</p><p dir="RTL">- التھاب القولون أو أي أمراض الجھاز الھضمی أو أمراض الكلى أو غیرھا من مشاكل فی المسالك البولیة، بما فی ذلك انخفاض وظائف الكلى</p><p dir="RTL">(يزيدمستوي إيمیستا فی الدم عند المرضى الذين یعانون من انخفاض في وظائف الكلى مما يؤدﯨ إلى حدوث آثار جانبیة في الجھاز العصبی المركزي إذا لم</p><p dir="RTL">يتم تعديل الجرعة وفق الوظائف الكلى)</p><p dir="RTL">- أي اضطرابات في الجھاز العصبی المركزي مثل الھزات الموضعیة أو نوبات الصرع (نوبات)</p><p dir="RTL">- مشاكل الكبد</p><p dir="RTL">قد يحدث لك نتیجة إيجابیة فى (اختبار كومبس) مما يدل على وجود الأجسام المضادة التی قد تدمر خلايا الدم الحمراء .</p><p dir="RTL">سوف یناقش طبیبك ذلك معك.</p><p dir="RTL">أخبر طبیبك إذا كنت تتناول أدوية تسمى حمض فالبرويك أو فالبروات الصوديوم (انظر استخدام أدوية أخرى أدناه).</p><p dir="RTL">الأطفال</p><p dir="RTL">لاينصح استخدام إيمیستا فی الأطفال أقل من سنة واحدة من العمر أو الأطفال الذين یعانون من مشاكل فی الكلى.</p><p dir="RTL">استخدام أدوية أخرى</p><p dir="RTL">يرجى إخبار الطبیب أو الصیدلی إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، بما فیھا تلك التی تم الحصول علیھا دون وصفة طبیة.</p><p dir="RTL">أخبر طبیبك إذا كنت تتناول جانسیكلوفیر الذي یستخدم لعلاج بعض العدوى الفیروسیة.</p><p dir="RTL">أيضا، أخبر طبیبك إذاكنت تتناول حمض فالبرويك أو فالبروات الصوديوم (تستخدم لعلاج الصرع والاضطراب الثنائی القطب،</p><p dir="RTL">والصداع النصفي، أو انفصام الشخصیة) أو أي أدوية تزيد من سیولة الدم مثل وارفارين.</p><p dir="RTL">سوف یقرر طبیبك ما إذا كان یجب استخدام إيمیستا بالاقتران مع ھذه الأدوية.</p><p dir="RTL">الحمل والرضاعة الطبیعیة</p><p dir="RTL">من المھم أن تخبر طبیبك إذا كنتى حاملا أو تخططین للحمل قبل تناول إيمیستا . لم یدرس تأثیر إيمیستا فی النساء الحوامل.</p><p dir="RTL">لاينبغی أنتتناولي إيمیستا أثناء الحمل ما لم یقرر طبیبك أن الفائدة المرجوة، تبرر الخطر المحتمل على الجنین .</p><p dir="RTL">من المھم أن تخبري طبیبك إذا كنت ترضعین طفلك طبیعیا أو إذا كنت تنوي ذلك قبل تناول إيمیستا .</p><p dir="RTL">كمیات صغیرة من ھذا الدواء قد تنتقل إلى حلیب الثدي وربما يؤثر على الطفل. لذا،</p><p dir="RTL">سوف یقرر طبیبك ما إذا كان یجب استخدام إيمیستا أثناء الإرضاع من الثدي.</p><p dir="RTL">إسأل طبیبك أو الصیدلی للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL">القیادة واستخدام الآلات</p><p dir="RTL">ھناك بعض الآثار الجانبیة المرتبطة بھذا المنتج (مثل الرؤية، والسمع، أو الشعور بشيء غیر موجود ھناك، والدوخة، والنعاس،</p><p dir="RTL">. ( والإحساس بالدوران) التی قد تؤثر على قدرة بعض المرضى على قیادة السیارة أو تشغیل الآلات (انظر الفقرة 4</p><p dir="RTL">معلومات ھامة عن بعض المكونات فی إيمیستا</p><p dir="RTL">يحتوي ھذا المنتج الطبیعلي حوالي 20 ملجم من الصوديوم لكل جرعة تحتوي على 500</p><p dir="RTL">ملجم ويجب أن یؤخذ ذلك بعین الاعتبار من قبل المرضى الذين یتبعون نظام غذائی محدد الصوديوم .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سیتم إعداد إيمیستا ويعطى لك من قبل الطبیب أو أخصائی رعاية صحیة آخر . سیقرر طبیبك كم تحتاج من إيمیستا.</p><p dir="RTL">البالغین والمراھقین</p><p dir="RTL">الجرعة المعتادة من إيمیستا للبالغین والمراھقین ھى 500 ملجم / 500 ملجم كل 6 ساعات أو 1000 ملجم / 1000 ملجم كل 6 أو 8</p><p dir="RTL">ساعات. إذا كان لديك مشاكل فی الكلى أو وزن أقل من 70 كجم، قد يخفض طبیبك الجرعة.</p><p dir="RTL">الأطفال</p><p dir="RTL">25 ملجم / كجم / جرعة كل 6 ساعات. / 15 أو 25 / الجرعة المعتادة للأطفال سنة واحدة من العمر أو أكثر ھي 15</p><p dir="RTL">لاينصح إيمیستا لدى الأطفال دون السنة الأولى من العمر والأطفال الذين یعانون من مشاكل فی الكلى.</p><p dir="RTL">طريقة التناول</p><p dir="RTL">30 دقیقة للحصول على جرعة أقل من أو تساوى 500 ملجم / 500 ملجم أو &ndash; يعطى إيمیستا عن طريق الحقن الوريدى (فی الوريد) خلال 20</p><p dir="RTL">60-40 دقیقة للحصول على جرعة أكبر من 500 ملجم / 500 ملجم. قد تباطأ معدل التسريب إذاكنت تشعر بالغثیان.</p><p dir="RTL">إذاكنت تناولت إيمیستا أكثر مما يجب</p><p dir="RTL">ويمكن أن تشمل أعراض الجرعة الزائدة التشنجات (النوبات)، والارتباك، والھزات، والغثیان، والتقیؤ،</p><p dir="RTL">وانخفاض ضغط الدم وبطء معدل ضربات القلب. إذا كنت تشعر بالقلق أن كنت قد أعطیت الكثیر من إيمیستا ،</p><p dir="RTL">اتصل بطبیبك أو محترف رعاية صحیة آخر على الفور.</p><p dir="RTL">إذا كنت قد نسیت تناول إيمیستا</p><p dir="RTL">إذا كنت تشعر بأنك قد فوت الجرعة، اتصل بطبیبك أو محترف رعاية صحیة آخر على الفور .</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام ھذا الدواء، إسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جمیع الأدوية، يمكن أن یتسبب إيمیستا فی أعراض جانبیة، وإن لم یكن تحدث للجمیع .</p><p dir="RTL">يتم تعريف تردد الأعراض الجانبیة المحتملة المذكورة أدناه باستخدام المصطلحات التالیة :</p><p dir="RTL">&bull; شائع جدا: يؤثر في أكثر من 1 مستخدم في 10 مستخدمین</p><p dir="RTL">&bull; شائع: يؤثر فى 1 إلى 10 مستخدمین في 100 مستخدم</p><p dir="RTL">&bull; غیر شائع: يؤثر فى 1 إلى 10 مستخدمین في 1000 مستخدم</p><p dir="RTL">&bull; نادر: يؤثر فى 1 إلى 10 مستخدمین في 10000 مستخدم</p><p dir="RTL">&bull; نادر جدا: يؤثر في أقل من 1 في 10000 مستخدم</p><p dir="RTL">&bull; غیر معروف: لا يمكن تقدير التردد من البیانات المتاحة</p><p dir="RTL">تحدث الأعراض الجانبیة التالیة نادرا، ولكن إذا حدثت، أثناء تلقی أو بعد تلقی إيمیستا ، يجب إيقاف الدواء واتصل بطبیبك فورا .</p><p dir="RTL">&bull; الحساسیة بما فی ذلك الطفح الجلدي، وتورم فی الوجھ والشفتین واللسان و / أوالحلق (مع صعوبة فی التنفس أو البلع)، و /</p><p dir="RTL">أو انخفاض ضغط الدم</p><p dir="RTL">&bull; تقشیر الجلد (انحلال البشرة السمي)</p><p dir="RTL">&bull; التفاعلات الجلدية الشديدة (متلازمة ستیفنز جونسون و حمامی عديدة الأشكال)</p><p dir="RTL">&bull; الطفح الجلدي الشديد مع فقدان الجلد والشعر (التھاب الجلد التقشري)</p><p dir="RTL">الأعراض الجانبیة المحتملة الأخرى:</p><p dir="RTL">شائعة</p><p dir="RTL">&bull; الغثیان والقيء والإسھال. يحدث الغثیان والقيء بشكل متكرر أكثر فی المرضى الذين یعانون من انخفاض عدد خلايا الدم البیضاء</p><p dir="RTL">&bull; تورم واحمرار على طول الوريد ويؤلم للغاية عند لمسه</p><p dir="RTL">&bull; الطفح</p><p dir="RTL">&bull; خلل في وظائف الكبد يتم الكشف عنھ بواسطة اختبارات الدم</p><p dir="RTL">&bull; زيادة فی بعض خلايا الدم البیضاء</p><p dir="RTL">غیر شائع</p><p dir="RTL">&bull; احمرار محلی في الجلد</p><p dir="RTL">&bull; ألم محلی وتشكل كتلة ثابتة فی موقع الحقن</p><p dir="RTL">&bull; حكة الجلد</p><p dir="RTL">&bull; خلايا النحل</p><p dir="RTL">&bull; الحمى</p><p dir="RTL">&bull; اضطرابات الدم التی تؤثر على مكونات خلايا الدم ويتم الكشف عنھا عادة بواسطة اختبارات الدم (قد يكون من أعراضھا التعب وشحوب الجلد،</p><p dir="RTL">وكدمات طويلة بعد الإصابة)</p><p dir="RTL">&bull; تغیر غیر طبیعي في وظائف الكلى والكبد والدم ويتم كشفه عن طريق تحلیل الدم</p><p dir="RTL">&bull; الھزات وارتعاش العضلات غیر المنضبط</p><p dir="RTL">&bull; المضبوطات (نوبات)</p><p dir="RTL">&bull; اضطرابات نفسیة (مثل تقلب المزاج وضعف الحكم)</p><p dir="RTL">&bull; الرؤية، والسمع أو الشعور بشيء غیر موجود ھناك (الھلوسة)</p><p dir="RTL">&bull; الارتباك</p><p dir="RTL">&bull; الدوخة، النعاس</p><p dir="RTL">&bull; انخفاض ضغط الدم</p><p dir="RTL">نادرة</p><p dir="RTL">&bull; العدوى الفطرية (داء المبیضات)</p><p dir="RTL">&bull; تلون الأسنان و / أو اللسان</p><p dir="RTL">&bull; التھاب القولون مع الإسھال الشديد</p><p dir="RTL">&bull; اضطرابات فی الذوق</p><p dir="RTL">&bull; عدم قدرة الكبد على أداء الوظیفة الطبیعیة</p><p dir="RTL">&bull; التھاب الكبد</p><p dir="RTL">&bull; عدم قدرة الكلى على أداء الوظیفة الطبیعیة</p><p dir="RTL">&bull; تغیرات فی كمیة البول وتغیرات فی لون البول</p><p dir="RTL">&bull; مرض فی الدماغ، الإحساس بالوخز (الإبر والدبابیس)، ورعاش محلي</p><p dir="RTL">&bull; فقدان السمع</p><p dir="RTL">نادرة جدا</p><p dir="RTL">&bull; تراجع الشديد فی وظائف الكبد نتیجة لالتھاب (التھاب الكبد المداھم)</p><p dir="RTL">&bull; التھاب المعدة أو الأمعاء (التھاب المعدة والأمعاء)</p><p dir="RTL">&bull; التھاب الأمعاء مع إسھال دموي (التھاب القولون النزفي)</p><p dir="RTL">&bull; تورم واحمرار اللسان ، فرط نمو الزوائد العادية على اللسان مما يعطیھا مظھر شعر، حرقة، واحتقان الحلق، وزيادة فی إنتاج اللعاب</p><p dir="RTL">&bull; ألم فی المعدة</p><p dir="RTL">&bull; الإحساس بالدوران (الدوار)، والصداع</p><p dir="RTL">&bull; الرنین فی الأذنین (طنین)</p><p dir="RTL">&bull; ألم فی العديد من المفاصل، وضعف</p><p dir="RTL">&bull; عدم انتظام ضربات القلب، نبض بقوة أو بسرعة</p><p dir="RTL">&bull; عدم الراحة فی الصدر، صعوبة فی التنفس، وتنفس سريع وسطحی بشكل غیر طبیعي، ألم فی العمود الفقري العلوي</p><p dir="RTL">&bull; توھج، وازرقاق في الوجه والشفاه وتغیرات نسیج الجلد، والتعرق المفرط</p><p dir="RTL">&bull; حكة الفرج عند النساء</p><p dir="RTL">&bull; تغیرات فی كمیات من خلايا الدم</p><p dir="RTL">&bull; تفاقم فی مرض نادر مرتبط بضعف العضلات (تفاقم الوھن العضلی الوبیل)</p><p dir="RTL">إذا أصبحت أي من الأعراض الجانبیة خطیرة، أو إذا لاحظت أي أعراض جانبیة غیر مذكورة فی ھذه النشرة، يرجى إخبار الطبیب أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعیدا عن متناول ونظر الأطفال.</p><p dir="RTL">لا تستخدم إيمستا بعد تاريخ انتھاء الصلاحیة المذكور على العبوة. تاريخ انتھاء يشیر إلى الیوم الأخیر من ذلك الشھر.</p><p dir="RTL">لا تخزن في درجة حرارة أعلى 30 درجة مئوية.</p><p dir="RTL">بعد إعادة تكوين:</p><p dir="RTL">المحلول المخفف یجب استخدامه على الفور. ينبغی ألايتجاوز الفاصل الزمنی بین بداية إعادة تكوين المحلول ونھاية التسريب فی الوريد ساعتین</p><p dir="RTL">فى درجة حرارة 30 درجة مئوية.</p><p dir="RTL">لا تجمد المحلول المكون.</p><p dir="RTL">یجب عدم التخلص من الأدویة في میاه المجاري أو قمامة المنزل. اسأل الصیدلي كیف تتخلص من الأدویة التي لم تعد بحاجتھا. لأن ھذه الاعتبارات</p><p dir="RTL">ستعمل على حمایة البیئة.</p><p dir="RTL">المعلومات التالیة موجھة لأصحاب المھن الطبیة أو الرعاية الصحیة فقط:</p><p dir="RTL">كل قارورة للاستخدام مرة واحدة فقط.</p><p dir="RTL">إعادة التكوين</p><p dir="RTL">يجب أن یتم نقل محتويات كل قارورة إلى 100 مل من محلول الحقن المناسب (انظر التعارض وبعد إعادة التكوين): 0.9 ٪ كلوريد الصوديوم.</p><p dir="RTL">فی ظروف استثنائیة حیث لا يمكن استخدام 0.9 ٪ كلوريد الصوديوم لأسباب طبیة، يمكن استخدام 5٪ جلوكوز بدلا من ذلك.</p><p dir="RTL">الإجراء المقترحة وإضافة مايقرب من 10 مل من محلول الحقن المناسب للقارورة.</p><p dir="RTL">وھز جیدا ثم انقل الخلیط الناتج إلى حاوية محلول الحقن فی الوريد.</p><p dir="RTL">تنبیه: الخلیط لیس للحقن الوريدي المباشر.</p><p dir="RTL">كرر ذلك مع 10 مل إضافیة من محلول الحقن لضمان نقل كافة محتويات القارورة إلى محلول الحقن فی الوريد.</p><p dir="RTL">يجب رج الخلیط الناتج حتى یصبح واضح.</p><p dir="RTL">تركیز المحلول بعد إعادة التكوين بعد الإجراء أعلاھ ھو حوالي 5 ملجم / مل لكل من إيمیبینیمو سیلاستاتین</p><p dir="RTL">الاختلافات فی اللون من الشفافیة إلى الأصفر، لا تؤثر على فعالیة المنتج.</p><p dir="RTL">عدم التوافق</p><p dir="RTL">ھذا المنتج الطبی غیرمتوافق كیمیائیا مع لاكتات ، وينبغی ألا يعاد تكوينه فی مذيبات تحتوي على لاكتات. ومع ذلك،</p><p dir="RTL">فإنه یمكن إعطاءه في نظام وريدي یتم حقن لاكتات من خلاله.</p><p dir="RTL">يجب عدم خلط ھذا المنتج مع المنتجات الطبیة الأخرى باستثناء تلك المذكورة فی إعادة التكوين .</p><p dir="RTL">بعد إعادة التكوين</p><p dir="RTL">يجب استخدام المحلول المخفف على الفور. ينبغی ألايتجاوز الفاصل الزمنی بین بداية إعادة التكوين ونھاية التسريب فی الوريد ساعتین فى</p><p dir="RTL">درجة حرارة 30 درجة مئوية.</p><p dir="RTL">يجب التخلص من أي مواد غیر مستخدمة أو فضلات وفقا للمتطلبات المحلیة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المواد الفعالة ھي إيمیبینیمو سیلاستاتین.</p><p dir="RTL">تحتوي كل قارورة على إيمیبینیم أحادى الھیدرات یعادل 500 ملجم إيمیبینیمو سیلاستاتین صوديم یعادل 500 ملجم سیلاستاتین.</p><p dir="RTL">- المواد الأخرى الغیر فعالة ھي صوديوم ثنائي الكاربونات 20 ملجم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">إيمیستا عبارة عن بودرة بیضاء إلى أصفر فاتح جاھزة للحقن في قارورة من الزجاج. تحتوي كل عبوة على 1 أو 10 أو 25 قارورة.</p><p dir="RTL" style="text-align:right">لا يتم تسويق كافة العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>صنع بواسطة إیھ سي إس دوبفار<br />لصالح<br />الدوائیة<br />الشركة السعودیة للصناعات الدوائیة والمستلزمات الطبیة.<br />المملكة العربیة السعودیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم الموافقة على ھذه النشرة بتاریخ أبریل 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                IMESTA' IV 500 mg/500 mg powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains imipenem monohydrate equivalent to 500 mg imipenem anhydrate and
cilastatin sodium equivalent to 500 mg cilastatin.
Each vial contains sodium bicarbonate equivalent to approximately 20mg of sodium.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion.
White to light yellow powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>IMESTA&#39; is indicated for the treatment of the following infections in adults and children 1 year<br />of age and above (see sections 4.4 and 5.1):<br />&bull; complicated intra-abdominal infections<br />&bull; severe pneumonia including hospital and ventilator-associated pneumonia<br />&bull; intra- and post-partum infections<br />&bull; complicated urinary tract infections<br />&bull; complicated skin and soft-tissue infections<br />&#39;IMESTA&#39; may be used in the management of neutropenic patients with fever that is suspected to<br />be due to a bacterial infection.<br />Treatment of patients with bacteraemia that occurs in association with, or is suspected to be<br />associated with, any of the infections listed above.<br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />The dose recommendations for &#39;IMESTA&#39; represent the quantity of imipenem/cilastatin to be<br />administered.<br />The daily dose of &#39;IMESTA&#39; should be based on the type and severity of infection, the<br />pathogen(s) isolated, the patient&#39;s renal function and body weight (see also section 4.4 and 5.1).<br /><u>Adults and adolescents</u><br />For patients with normal renal function (creatinine clearance of &gt;70 ml/min/1.73 m2), the<br />recommended dose regimens are:<br />500 mg/500 mg every 6 hours OR<br />1000 mg/1000 mg every 8 hours OR every 6 hours<br />It is recommended that infections suspected or proven to be due to less susceptible bacterial<br />species (such asPseudomonas aeruginosa) and very severe infections (e.g. in neutropenic<br />patients with a fever) should be treated with 1000 mg/1000 mg administered every 6 hours.<br />A reduction in dose is necessary when:<br />- creatinine clearance is &le; 70 ml/min/l.73 m2 (see Table 1) or<br />- body weight is &lt; 70 kg. The proportionate dose for patients &lt; 70 kg would be calculated using<br />the following formula:</p><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAArcAAAChCAIAAABS7wCPAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAAAhdEVYdENyZWF0aW9uIFRpbWUAMjAyMDowNjowNCAxNToxMjozNOmqDPoAACQFSURBVHhe7d13fBVV2gdwA4QQhIQqqFgoAvYWF0QBQZqKgvABxDUgWNC1sKAYXQtSZBEXLLgKfLCwoKyCqItIiYgKCAiCWBBFKUJCDSRAElJ5f87z3PPmzsy9ucktSeD3/SM55zln+ty5Z2bunIk6fvz4KUREREQOlfQ/ERERkTe2EoiIiMgdWwlERETkjq0EIiIicsdWAhEREbljK4GIiIjcsZVARERE7thKICIiIndsJRAREZE7thKIiIjIHVsJRERE5I6tBCIiInLHVgIRERG5YyuBiIiI3LGVQERERO7YSiAiIiJ3bCUQERGRO7YSiIiIyB1bCUREROSOrQQiIiJyx1YCERERuWMrgYiIiNyxlUBERETu2EogIiIid2wlEBERkTu2EoiIiMgdWwlERETkjq0EIiIicsdWAhEREbljK4GIiIjcsZVARERE7thKICIiIndsJRAREZE7thKIiIjIHVsJRERE5I6tBCIiInLHVgIRERG5YyuBiIiI3LGVQERERO7YSiAiIiJ3bCUQERGRO7YSiIiIyB1bCUREROSOrQQiIiJyx1YCERERuWMrgYiIiNyxlUBERETu2EogIiIid2wlEBERkTu2EoiIiMgdWwlERETkjq0EIiIicsdWAhEREbljK4GIiIjcRR0/flyTFLQvvvhi/fr1SAwbNiwqKkqCAZoxY0ZaWlrt2rUHDRqkofJh5syZ+/fvj4+Pv+uuuzR0EsvLy5s8eTISXbp0ueiiiyQYQpMmTcLfCy+8sGvXrhIpJ2TGWrZseeONNyKRkZHxxhtvING/f//TTz/9zxrhtGPHjg8++ACJIUOGnHrqqRKk8q+goODll19Gom3btldddZUEy5XMzMypU6ci0bt373POOUeCoVJYWPjSSy8h0aZNm9atW0uw4kErgUJl+PDhVSz4bGgoYJdccgkGvOCCCzRfblxxxRWYsebNm2v+5HbkyBFrC1d5++23NRRSMnI0yDRfbsiMDRgwQLK///67RFatWiWRsEpOTpbJ7d69W0NUEeTk5MiG+9e//qWhcgZ7lMzhkiVLNBQ6ubm5MvLnnntOQxUQ7zgQERGRu6DuOGzfvv2xxx5D4sUXXzzzzDMleBL6+uuv5bLSihUr9u/fjwRa0JUqBdQCmzFjxoIFC5BYuHDhsWPHcMr+008/SVHZmjVr1v/+9z8kZMaaNGnyyy+/SNFJDmsDf6OjoytXriyR4D399NNYvQUFBbLOBw4cOH36dCkqW88+++ymTZtiY2Plqmx6evrDDz+MxK5du9auXYvE8uXLI3AptbCwEKdlSMyePRs7JBLvvvsuTtGswhLr27evpopjplLsIFOmTKlTp45m6JRTbr/99vz8/MzMTJyjIzt+/PhHHnlEisoDzBvmEIm9e/fiAI7Ep59+2rlzZ6swBAYNGoRlz8rKWrx4MbKjRo36xz/+IUUVj1xSKJ0NGzZYV1Oq/Pzzzxo6Kb333nuyHozA7ziYmxSi/NxxSEpK0nmy8I5DWLVr105XtKX83HHo2LEj5qdevXqSxYFP5tCIzB0HA182Ml00GjRUcjKGQKC5H+AgKSkpUpNE9erVddVYytsdB3MvwAjtHYe6devqeC2840BEREQnoArZSnj88cfrW9DM0VCZ6tu3b57lgQce0FDAJk6cKMO2bNlSQ+UDTtpkxi6++GINUdh8+eWXWNVyUb10srKy5EMxc+ZMDQUBu6WMbeHChZgxuY8GOEG0doq8TZs2SSTCkpKSZAb69euH2Tv77LO1oCRkDIa5lfbZZ59pyKNq1apSpHkPM0hycrJEzjjjDImEw8qVK2VzpKamaqjcy8zMxGo5cuSI5suZ6Oho2XDbtm3TUEgdOHAAIz969KjmK7IK2UrIzs5Ot2i+3AjmRnWAv2OIvJI+0kmlFsyqRotZPhTBNDUM8xHztVuG8DcZpYNWEWYvIyND80Ewy1Il4B86mJqBDxKM/Px82Rzl5LwocOX2sGaEdQuW/8UPRCmXocDjLxbsxJLVYiKiCiImJkaOY/gOLvY4JhVycnJkkJo1a2oB0QmqNK2EgwcPVrPs3LlzpWXjxo0SKbfXl4iIXDVs2FCOY7m5uXIc2717t5Z5O3bsmFRYsmSJDHLppZdqGdEJ6kS4HkJEREThUJr+Eg4ePNigQQMk5syZ07NnTyTeeeedO++8U4pKegkuKysrJydHM0WgwR4bG6sZC1r6mZmZSAwZMuTDDz9E4o8//kA1q9BdXFyc7QZqRkZGYWGhZqyLjdWrV9eMN18z5meQRx555JVXXkEi8P4SDJyUbNq0yfSXILeZpUg4l8XGOYhRq1Yt//e8CwoKDh8+rBmLGeTKK6/8/vvvTX8JgUwFo8IIJVjUqaeean4O5suhQ4c05c0sfnZ2tvRYYGO2i3NZjNq1a2vKUoo1ZgbBtDBFCdocOXIkPz9fM345pxIdHY2/pr8E7Ku2W+/OQWSNpaamXnbZZUgkJSXZHkz3tSxO5vdWixYt2rhxIxLjxo1z3ZO3bt3aokULJJz9JfhafOcaw3bE1tSMXziq2O4fY/389ttv2CUeffRRZLFfBd9z85YtW6Tb6cTERPk1otlhZCVj0V577TUkbrnlljZt2lglpedr8bEP1KhRAwmz9T/44IP7778fieTkZNvVC9su7dxhDFtNwwxiVjIOXzj6WYXK17CGr0Fw0Jbt4qe/BOxy2PE0UwSO/74O7/gikN/f2DaQgRUoHyXDDCKwpPJVtWfPnrPOOguJYPpL8LX4WC45KPnpL8E2Y4afxTdwLMIRSTNFOBffKMUgfx71SiotLQ2rGPBVLZFZs2ZJBEdniQTuwQcflGFtcLDTGh7Sw0mJ4BtXB/Zo2bKllllwiNECh2HDhmklb8OHD9caDiHsoRnbUkZl4KtainxxDmKg9aaVfEADRat6mEFsPTTjgCIVnLBjSJ2EhAQNecN+IhV8wQFLqzps2LBB6jz55JMa8nbfffdJBbRmNOSAby+pI3DQ1wKH/fv3ayVvZhA/PTRfe+21UqdY+/bt02E8JG76S8AXoUQMX4P4sXfvXq1aHDQOAhzETw/NnTp1kiKbqVOnag0PNEG0rDhff/21DuMgFfr376/5UJgwYYKMFkd/iUi2b9++kg2JiRMnymhtevfuLRVwFqQh36SmsXPnTi1wQKNEK3nbtWuXVFi2bJlEXn75ZYkYEvcDZ0da1UPiWIGS9dNfAtaq1LHBVtAaDrfddpvUkayZioHmlBQZ2EO0zNK1a1eJh6SHZuzbMhJD4vj6l6yf/hIGDBggdWzGjBmjNXw77bTTtLY3tHi0hkPDhg21krcFCxZoDQfecSAiIiJ3JbvjIA9JZ2Zm4kwCCZwzNWrUCInt27evXr0aifPOO09uE+CcGH/9wClpSkoKElu3bnV9qDQuLu7cc89FApNAGokdO3bgxAWJF154ASfWSEybNs12V0KsXLlyypQpSGzcuNE2J2gx4XQQi4BTT2T//ve/Y2xSJA4fPozGNRLbtm1DTQkWVbNmzcaNGyNhZswI/o5DgwYNpEPTrKwsnEdKkTjrrLPkKlaLFi1stx5ku2RnZ2/ZskUiNs2aNZMLX7a1gXP3zZs3I5Geno4TFwkKM8hNN92EFWLuOOTl5cnb+bDF//3vfyMxZMgQ7AlI9OrVS24oYBEOHjyIc5d77rkH2Ysvvlh68m7durVsUz/++9//4i9OieQC3Y033oiTACTQ9pfFx6aX5R0+fDjO+GvUqPH6668j27RpU3npHLaadHr90Ucfyaw+88wz2DOR6Nevn1x7L3aNYWxypfT8888vOgh2wltuuQWJ6dOnDxw4EAkDMwNIYEVhB5BgUd9++6305H333Xe3b98eiVtvvdV2EV4u+l1zzTVyZRsfE0zRKlHYEHI52syYrDF8mh5//HEksKLuuOMOJIyePXsWe+lSLF68uHv37khgbDhNkaArP3ccOnfu/MUXX2BPkKv3RkJCAnYqJPB5l50NW9n1BhNO72SH6dSpk6xkJOrVq2cV2ska69Onz7vvviuR4OGYILvf0qVLZbpywMFnEJvmzxpBwMFHtqlz8RMTE/G3R48ec+fORQIHAemxG9tl1qxZSCQlJdneRIqzavzFYfznn39GAocvHI2tEruWLVvKx1MOAmaQ9evXD7LeQ4uPSe/evZHA5x2fXySMSy65BH+x49k6qMAcyuR8DYJPBLYdEs47Dqi/Z88eJHCgs12uF/i8y72Ac845Rz6MZpC77rpr3bp1SGzYsAFHWhyUZFmM6667DifNSGANy29RbVPBJ6J58+ZIYMvKai/FHQccQKS7BXxe0tLSJChw0MPHEzPcoUMHZJ13HMyM4csUu4QEi4qPj5d3VGKdy0fewOTkJtGPP/6IY7gEAUeesWPHIoHd5oYbbpCgSE1NxUEeCdsgBr56AAl8SO33hf+8oBCY/Px8uTSBpdWQwwMPPCB1MB8a8uGdd96RmlhaDXnD+pUKONBryOPhhx+WIl9TQeNAKjjvOIiCggKp4LzjgGOuFMn9GydsXanw/vvva8gj+DsOxrBhw7TAY86cOVKEGdCQBStB4kOHDtWQw4gRI6SObcbM7QMcYTXkUWwPzfhYStF3332nIW9mxrBXaChgONjJsDNnztSQA76cUAEtNs07fPzxxzKSAwcOaMhiZuzee+/VkAOOmFJHblKYQQznHYeRI0dKEY5ZGvKGFolUWLt2rYYcpIKBL1ot8MDhRopsU8FXr8TRfNFQyYXwjkOdOnU074BGpAyLo6SGvOFoLhXQ/tOQb1IzTHccBJrLWhAKy5Ytk9Him1VDHhI3dxwMtLqkyDmIQItcKqAZqiEHNEmljmTNIE5ow0kdA9+piKN9rHkPtBF9DYKVJkXCecfh1VdflSJ812rIG77YpMJnn30mEZyWSMQG34hSwQmtbamDnUpDFnMvwCjFHQfs/DIsGs0a8ii2h2ac4koRmgga8obPoFRYuHChhjzuvPNOKdK8hxnEeccBDUEp0rwDDkpSAYcpDXnwjgMRERG5K7+thLi4uDWWjh07aigiunTpItO1XeSJjPr168vUhw8frqEy8tBDD8mcnMBv+/z222/n+/Dll19qJUtUVJSsjTlz5mgonFq1aiWT69Gjh4bKvV9//VVW3bhx4zDnn3/+uRZUQAMGDJD1f/7552soImSiEyZM0HzAqlatKsPK7blAmEHk5iwkJSVJRK48B2nFihUYldz7c9W3b1+ZnP36tm99+vSRQS6//HKJ4GweWbnPWyI4aZZRhenlq0uXLsXI5f2lEVOnTh1ZKD/3xebNmyefUxu5peWq/LYSKleufIWlVq1aGoqI2rVry3T9P3YYJmbq8oOPMoTGgcxJ3bp1NXTC2bhxYy8fVq5cqZU8ZG3ITdZwa9mypUyuAq38uXPnyqq77LLLMOcVurshfE3K+i/deyJKTSbapEkTzQcMrVgZ1v+vSYoyg3Tr1k0i2LclEvjXth/4IseorrvuOs074IxIJhf4T7jMIE2bNpVIQkICsvJ7lxIxi9+1a1cNhRT2f4xcfn4UMWj6yELZfjBXVL9+/eRzaiM/MnPFOw5ERETkrjSthI8//nisD8nJyVqp4luyZIkulbcnnnhCa5zc0H5Psezbt0/WjOkiZvr06chOmjRJKvzzn/+UeOBq1Kghw+KsWkYuv22GZcuWSeT9999HhRUrVkjWXNtMS0uTCM48ZCTycIQTzqKkgh9lckmpAhk3bpys7cjci4mMVatWyUK9+uqr2Ae2bt0qWXn0IEht2rSRXeubb76R0QqsSa0RhMOHD+voHOShgHLogw8+0Fn05qsbInr55ZdlF5owYYKuLMvy5cu1hm/bt2+XYX2RJ/i86K8YA2CecQiEr6cPjGKfcfAjrM84GL56VTLC8YyD6VXJKcLPOBhXePeq5DRv3jwZia1XJTQjJBuMzZs3y8idvSrZnj5w9qq0fv16idiYQfw84+CLn16VQviMg+lVyam8PePglJubq5V8qEDPOESyV6WqVatqgUOxzzgYfnpVMrSqB8YpcdOrklMpnnEQwfSqZJhnHAxbr0p++HrGwcBOKBVC+4yD8NOrUjDPOBi2XpVGjx6tBQ7FPuPgB+84EBERkbuAWglohnTv3v3BBx9EqydAAwcOxCA46ddRVBxfffUV5hweffRRXRhv0rkQkc3TTz8te8iwYcNkF7JZv369VLjyyit1mIrvww8/lIUykpKSsLA4QdQaDtdff73UnD9/vqwZm+eff14q3HvvvTpMRHz33XcyA7169ZIZCMnv+HwZOnSoTEUcOXJEpj7W6hinRPLy8mTYpUuX6ugcIvywWLHM1sfpvs6itw0bNmhV8mHXrl26siyJiYmySteuXas1QiGgVgK+OBcvXoxjHD4zAVq1ahUGwV8dRcWxe/duzDnIq4mc6tSpo1WJiqhcubLsIfiykV3IBh9jqRAV2LuXKoR69erJQhk//PADFhZfV1rDoVKlSlLzwIEDsmZsfvvtN6lQ0g5Mg3Tw4EGZgerVq8sMaEF4mB3GkKlj/9EaASssLJRh09PTdVwOwb8NK7T++OMPmWdfR9oT+OmqUImOjtaVZcF+K6sUnyytEQq840BERETuym8r4dChQzEWeUm0H2hHS03px96/iy66CDXN2x9eeuklGVY6/CfjiSeekDUjPdhv3bpVskOHDpUKxq233ppnmThxotRZvXo1sr5ekVA6rVq1kpEPGzZMJmd7+mD69OlSYc2aNVLBdL1SCs8++6yMrcDtFdiuRo0aJYMsW7ZMZsBGesuPmIULF8r87Nu3T0MRkZycjIVNS0uTqdvedgGoIEVYIbJmbPx08BIOOKmV+QGZgdNPP13LPCQ+Y8YMqSZv2SidL774QkaSmpqqoZLr1asXxhDg6znKRM2aNTGH8nZmwMHZWug/Px0SKVvYmjI/8q4E6N69u0R8vQijRBo0aIBRma75Ro4cKSNfYr2mJ0iDBw+WsWk+FNatWyfjlJc0FVWuryXg6x+OB/A+KqkJmvcNB31bTckGMpWTClaIrBnNB7CStTiArVAKOmq/I5cKIdmUzsUvVikGCbeynR+ZuuvmkCLNlLUSbTipGeQ+FvxIZJ4Db8JGniwjaD5Eqy6EZH7ANRuksH7RyNYHzYeIjNM5hy6tBNSThrORn5+PeE5OjmT97JookjqAbG5urmY8MHKp2bBhw46WrKwsLfOGuFTw05tYdnY2auKv1JT3/gFacBKRURV11VVXIS7vMIQ6depITdMpKRIS8TVj8mYtOHjwoIY8Dh8+LEUyY7LeAvSXv/wFE01ISJBROaGVJzNWpUoVHcZD4meeeaZWdcC5kdTRATwwKonjpESrepj1gOmiZnR0tGTlTYARU716dZmuafI7SQWsOs0HQAY5++yzdWkd6tevL3XMbwgkLq9iA7P1zYeqSZMmMohsfT+cn0PsKogfO3ZMskeOHJGa5vOCQSRiZuDo0aMSkaxx6NAhiZuNWzXg++vm42B2fi0oQuJYfMmmpaVJRLIgy2Leimnm0yyLmUqxK8oM4iRTwRFGRmV7U6J/MnLDuSzODSRx8wE3K9lwDlIs5wFElkXepujKzCGOdah5/fXXS7xSpUoybHx8vFRwwjaVypr3MIvv3KVlJYNsCLNXmO2Cycl0nZuyffv2iF999dVSE4dxqWl+19WoUSOJ+DrSOreLkel5iaJ8xfg50vqaCrISN52ENm7cWCKBX6Exi2++HI22bdsi3qZNG6lpjifmxxZnnHGGRLAsOow3M4d+fp+BI4bWtpivQucgF1xwgRQ5Z1VgHUoFHHJ1GAM7hM3MmTP/fKzSt0DeCenLvHnztKrHgw8+qGXekpKStIaD6S9BXH755VrgMHv2bK3kgf0bcbRmJBtMfwnFwpFLxxUwM2NO33//vVbyAc0XreqAz5tW8mHTpk1a1cMMUmx/Ccbjjz8uw2KH01DofPTRRzJy2wseDfMayRkzZmioOKbzA6f9+/drJQt2Gy1wWLdunVbyQBtUy3xw9pfQrl07LfNm3gm5YMECDXlDY04qmP4SjDVr1khRKYwZM0ZGgsOHhiw4okncac+ePVJH3gnpNHXqVKlgjBs3Tst88NNfQteuXVEhLi5O8yUhI/cjNTVVq3pogW8pKSlatTjmnZA2aMxpDQfTX4KBrwct8xZIfwnFMp0f9O7dW0PeJk6cKBWMV155Rcs8JB6S/hKK5eedkEb//v21tgX7j8SD6S/BwL4tIzEk7qe/BGPAgAFSxwafQa3hYN4JaeOnvwQD5+da2xuOMFrDgb9eJCIiIndRaClo0mPjxo04b9OMG5wqmStdNmiP+O8HFM1G22vWfA3Spk2bzp07a8bbp59+WvR5UJxO3XfffZrx9uOPP9p+lvjMM89ERf251Gh2IXv11Vd36dJFimwWLlz4zTffaKZU6tWr98ADD2gmMGbGnLCM5raIKzTbx48frxlvSUlJ/i+j4dTZ9oOsxx57TH7jOWXKlL1799auXbvY3i+eeOIJnDEggROdkHdsvHnz5vfeew+JESNGuFwTs649SlfQPXv2DPBVQ2YQJ+dURo0apSlv99xzzxlnnIEEzrOzrIu6s2fPPnTokFXoDju23B2rW7euPOz35ptv4izQKvRy8803X3HFFUhs2bLl3XfflWBRmEnMKhI46bd18Xv33XeX+n2eY8eOleXNzs7GeYYEwTkV45FHHpHfas2YMcP191833XST3BXCapf7JjhF3rRpk1Xo7rLLLpNrtrVq1YqOjpag6Nat29KlS7H45hZM4HxtSmP48OHmZ3eiFIP4sm3btv/85z+aKQLHJRydNOMN6xNrVTOWp556yvUjdvjw4RdffFEzpTVs2DB5XRA+cfjcSbAoHDPNrQSxZs2aRYsWacYycuRI/C0oKJDuH7DPm8vvNnPmzPG/GxSradOmd9xxh2Z8mDt37k8//aQZ6/5gYmIiEkePHp04cSISGIN5iVRJ4SvM9BAvZPELCwvHjBmDRIcOHdq1a2eV2H344YfyC3EbP4PgCxpf05op4rrrriv2/VIvvPCCHKZs+vfv37x5c83Y/HlBgSgUwnrHofwrtodm45NPPpGa+/bt01A54+uOQ0gU20OzgS9Uqfn1119ryCOYOw5EFDjecSAiIiJ3bCVQsDIyMjZaOnToMMcS4S7zKOT69Okjm1K27I8//qgFZW3v3r0ySw899BBmL8I9KxCdhHg0p2B9/vnnCR49LSdSD8QnpxYtWsimfOyxx7BZ0f7TgrL29ttvy57WpUsXzN7NN9+sBUQUHmwlEBERkTuXZxx27NgR5G/76aQyd+7cefPmITF69OhmzZpJ8CT0yiuvrF69GonXX389Pj5egq4++uij999/H4mRI0dGuJeqkhoxYkRKSkpMTMxbb72loaDNnz9/9uzZSDz99NO2J55s1q9fL0/NDB48uFOnTkhg3S5fvhyJyZMn821AROFz6623VrGeb3JpJcyaNSvCHc4TERFR+ZGeni7vEeUdByIiInLnci0hJyfH9JJNREREJ5vatWvL79BdWglEREREwDsORERE5I6tBCIiInLHVgIRERG5YyuBiIiI3LGVQERERO7YSiAiIiJ3fBKSiHzKy8srLCxEIiYmRiI5OTn4W6VKlcqVK0skfHB0ys3NRSI6OpovGiUqE/zgEZFP3bp1q1GjRqNGjSSblZWFLLz55psSCasdO3bI5NasWaMhIoosthKIiIjIHe84EEVIfn7+/v37NROY+Pj46tWra8Zy5MiRo0ePaqaI2NjYWrVqaSZomAQmhMT8+fPT09Ojo6Nvu+02ZFNTU1u3bo3Ea6+9ds899/xZNZwyMjKmTp2KRJs2bZo2bYpEgwYNeOuBKJLYSiCKkN9++83/i5Kd8B05ePBgzVhGjx49ZswYzRSRmJgYwrsAY8eOHTVqFBLZ2dny9lg0FKwSFZlWgvHZZ5/dcMMNSOzcubNhw4YSJKIIYKuciIiI3PFaAlF4FRYWrlu3Donc3Fy5jF+sXbt2/e1vf0PCXEtIT0//9ddfkTh69Kg8ZWCDc/24uDgkGjduXL9+fQmWVEZGxi+//IKEmUq3bt3kvXALFy7E35SUlPvvvx+JCF9LOHDgwNq1a5HAMspVjauuukpmjIjCC60EIgoffONWsbz55psaKo4Z5I033pDIggULJLJv3z6J2JhBpk+frqGSW7RokYxk7969GvKWmZkpFaZNm6ahyBo/frzMAJpcGiKicOIdByIiInLHVgJReMXGxv5k6dWrl4Z8m2lJTk6WQXr37q0FRERlga0EovCqVKlSc0t8fLyGfBts+eSTTwIfhIgofNhKICIiInd8xoGoHJEf8A8cOHD69OkSEZ9++mmPHj2QSE1NdX2EITMzU3pVmjJlyl133SXBAKWlpUkfDH379r3wwguRiIuLc32CICsrSy5vOJ9xSE5OXrBggWaKuPLKKxMTEzVj2bx5M2ZSM3716dPnmmuu0YwlJyfn2LFjSEybNi0lJSUmJub555+XIiIKC/kRIxGVB/IDfnzNa94jrM84/P777zLs6tWrNeSDn2ccnnvuOSmyQRNBa3gsWbJEy4rz+uuv6zAOXbt2RQW0ZjRPROHBOw5ERETkjq0EIgqlQ4cO5RTx9ttvSzwlJSXBUqNGDS3zlp2dLTV79OghkSFDhkiEiMoKWwlEFEoxMTGVvEk8Nzd3oyUqKkoLvFWxXhgB1apVkwh7VyQqc2wlEJULx48fLywsbGCRvpYrCrl5icaBzDy/2olOJGwlEJW99u3bV61atVGjRrsskyZN0oJyb8mSJZhzuOOOO2TmzSUBIjoBsJVARERE7thKIKIS27NnT5YlJSVFQ0R0ImIrgYhKbPTo0fGWe++9V0NEdCJiK4GIiIjcsZVARCV2zTXXTPK2e/funZbjPjp9r1u3rtTMz8+XmjY7duyQCrYenYmoLMlTTERUhtq1a1elSpXTTz9d8w4VqIfm3NxcDfngq4fmWrVqaY0AsIdmosjgtQQiIiJyx3dCEpWZPyxI5OXl4W90dPS1115rldiF9Z2QW7dubdGiBRIrVqxo1aqVBF35eSfk9u3bt23bhgRO8aOiovC3devWUiSOHTu2bt06JAoKCgoLCyVYVOXKldu1a6eZ4nTr1m3p0qXVq1fPyMjQEBGFAa8lEJWZt956q4Olbdu2+OuriVAhnHvuubIso0ePxt+bbrpJCzx2794tFWJiYiRhE3gTgYgihq0EIiIicsc7DkRlZtSoUWPHjkUiOzu7it+OjbOysvbu3YvEDz/8sGfPHgkWVbt27YSEBCTq1atXs2ZNCQYoLy9v165dSGzfvn3Lli1IJCYmxsbGWoVq2rRp+ItJjxkzBgmc9/fr1w+Jnj17nnbaaUhs2LBh7dq1SKACqlWtWvXFF19E9rzzzuvQoQMS8mgDEjt27Pj111+R8KVZs2YdO3bUjLfvvvvum2++QaJt27bVqlWLioo699xzpYiIwsL6DSMRlYFnn30WjQPA97SGioOGhQxiM2jQIK0RhEWLFsnY0CLRkIfEnVatWiUVzDMONmhwSAXD1zMOxl//+let6jB+/HipU+yTFEQUErzjQERERO54x4GozOCEGJCoUaOGRIplBrGJjo6OiYnRTGktXry4e/fuSKSkpMh9BOPo0aOa8hYbG1u5cmUkfM0YzvurVauGxIEDB5588kkkBgwYcOmll1qF7jIyMkaPHo3E7bff3r59ewmK559//qmnnkIiKysLiyxBIgofthKISPlpJQRv27ZtzZs3R2L58uW2hyRtsrOz4+LikJg8efJ9990nQcFWAlGE8Y4DERERuWMrgYhU165d5cbBO++808KSn5+vZWVq5cqVMj+33367zCEvJBBFBlsJRPT/oiyZmZlbLRota9nZ2TI/aBzIHGoBEYUZWwlEZFe3bt1mFvOIphYEAV/wMk4ZoR+YqNSMiYmRCAaXiPxSkogihr9eJCKfrr/++q+++qpWrVr79+/XUNCSk5NvvPFGzbjp16/frFmzkNi+fft5552HBObh6quvtgqJKKJ4LYGIiIjc8VoCEfk0adKkLVu2xMbGIqGhoG3atGny5MmacZOQkCCvtUxLS5PnHkeMGNGkSROrkIgiiq0EIiIicsc7DkREROSOrQQiIiJyx1YCERERuWMrgYiIiNyxlUBERETu2EogIiIid2wlEBERkTu2EoiIiMgdWwlERETkjq0EIiIicsdWAhEREbljK4GIiIjcsZVARERE7thKICIiIndsJRAREZE7thKIiIjIzSmn/B+PIg4rDa8fTAAAAABJRU5ErkJggg==" alt="" width="250" height="58" vspace="0" hspace="0" border="0" style="width:250px;height:58px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>The maximum total daily dose should not exceed 4000 mg//4000 mg per day.<br /><u>Renal impairment</u><br />To determine the reduced dose for adults with impaired renal function:<br />1. The total daily dose (i.e. 2000/2000, 3000/3000 or 4000/4000 mg) that would usually be<br />applicable to patients with normal renal function should be selected.<br />2. From table 1 the appropriate reduced dose regimen is selected according to the patient&#39;s<br />creatinine clearance. For infusion times see Method of administration.<br />Table 1: Reduced dose in adults with impaired renal function and body weight &ge;70 kg*</p><table border="1" cellspacing="1" cellpadding="1" style="width:624px"><tbody><tr><td style="width:172px">Total daily dose for patients with normal<br />renal function (mg/day)</td><td style="width:128px">Creatinine clearance<br />(ml/min/1.73 m2)</td><td style="width:119px">&nbsp;</td><td style="width:202px">&nbsp;</td></tr><tr><td style="width:172px">&nbsp;</td><td style="width:128px">41-70</td><td style="width:119px">21-40</td><td style="width:202px">6-20</td></tr><tr><td style="width:172px">&nbsp;</td><td style="width:128px">dose in mg (interval<br />hrs)</td><td style="width:119px">&nbsp;</td><td style="width:202px">&nbsp;</td></tr><tr><td style="width:172px">2000/2000</td><td style="width:128px">500/500 (8)</td><td style="width:119px">250/250 (6)</td><td style="width:202px">250/250 (12)</td></tr><tr><td style="width:172px">3000/3000</td><td style="width:128px">500/500 (6)</td><td style="width:119px">500/500 (8)</td><td style="width:202px">500/500 (12)**</td></tr><tr><td style="width:172px">4000/4000</td><td style="width:128px">750/750 (8)</td><td style="width:119px">500/500 (6)</td><td style="width:202px">500/500 (12)**</td></tr></tbody></table><p>* A further proportionate reduction in dose administered must be made for patients with a body<br />weight &lt;70 kg. The proportionate dose for patients &lt;70 kg would be calculated by dividing the<br />patient&#39;s actual body weight (in kg) by 70 kg multiplied by the respective dose recommended in<br />Table 1.<br />** When the 500 mg/500 mg dose is used in patients with creatinine clearances of 6 to 20<br />ml/min/1.73 m2, there may be an increased risk of seizures.<br /><u>Patients with a creatinine clearance of &le;5 ml/min/1.73 m2</u><br />These patients should not receive &#39;IMESTA&#39; unless haemodialysis is instituted within 48 hours.<br /><u>Patients on haemodialysis</u><br />When treating patients with creatinine clearances of &le;5 ml/min/1.73 m2 who are<br />undergoing dialysis use the dose recommendation for patients with creatinine clearances of 6 to<br />20 ml/min/1.73 m2 (see table 1).<br />Both imipenem and cilastatin are cleared from the circulation during haemodialysis. The patient<br />should receive &#39;IMESTA&#39; after haemodialysis and at 12 hour intervals timed from the end of that<br />haemodialysis session. Dialysis patients, especially those with background central nervous<br />system (CNS) disease, should be carefully monitored; for patients on haemodialysis, &#39;IMESTA&#39;<br />is recommended only when the benefit outweighs the potential risk of seizures (see section 4.4).<br />Currently there are inadequate data to recommend use of &#39;IMESTA&#39; for patients on peritoneal<br />dialysis.<br /><u>Hepatic impairment</u><br />No dose adjustment is recommended in patients with impaired hepatic function (see section 5.2).<br /><u>Elderly population</u><br />No dose adjustment is required for the elderly patients with normal renal function (see section<br />5.2).<br /><u>Paediatric population</u> &ge;1 year of age</p><p>For paediatric patients &ge;1 year of age, the recommended dose is 15/15 or 25/25<br />mg/kg/dose administered every 6 hours.<br />It is recommended that infections suspected or proven to be due to less susceptible bacterial<br />species (such asPseudomonas aeruginosa) and very severe infections (e.g. in neutropenic<br />patients with a fever) should be treated with 25/25 mg/kg administered every 6 hours.<br /><u>Paediatric population</u> &lt;1 year of age<br />Clinical data are insufficient to recommend dosing for children less than 1 year of age<br />Paediatric population with renal impairment<br />Clinical data are insufficient to recommend dosing for paediatric patients with renal impairment<br />(serum creatinine &gt; 2 mg/dl). See section 4.4.<br /><u>Method of administration</u><br />&#39;IMESTA&#39; is to be reconstituted and further diluted (see section 6.2, 6.3 and 6.6) prior to<br />administration. Each dose of &le;500 mg/500 mg should be given by intravenous infusion<br />over 20 to 30 minutes. Each dose &gt;500 mg/500 mg should be infused over 40 to 60<br />minutes. In patients who develop nausea during the infusion, the rate of infusion may be<br />slowed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substances or to any of the excipients
• Hypersensitivity to any other carbapenem antibacterial agent
• Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of
beta-lactam antibacterial agent (e.g. penicillins or cephalosporins).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u><br />The selection of imipenem/cilastatin to treat an individual patient should take into account the<br />appropriateness of using a carbapenem antibacterial agent based on factors such as severity of<br />the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of<br />selecting for carbapenem-resistant bacteria.<br /><u>Hypersensitivity</u><br />Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in<br />patients receiving therapy with beta-lactams. These reactions are more likely to occur in<br />individuals with a history of sensitivity to multiple allergens. Before initiating therapy with<br />&#39;IMESTA&#39;, careful inquiry should be made concerning previous hypersensitivity reactions to<br />carbapenems, penicillins, cephalosporins, other beta-lactams and other allergens (see section<br />4.3). If an allergic reaction to &#39;IMESTA&#39; occurs, discontinue the therapy immediately. Serious<br /><strong>anaphylactic reactions require immediate emergency treatment.</strong><br /><u>Hepatic</u><br />Hepatic function should be closely monitored during treatment with imipenem/cilastatin due to<br />the risk of hepatic toxicity (such as increase in transaminases, hepatic failure and fulminant<br />hepatitis).<br />Use in patients with liver disease: patients with pre-existing liver disorders should have liver<br />function monitored during treatment with imipenem/cilastatin. There is no dose adjustment<br />necessary (see section 4.2).<br /><u>Haematology</u></p><p>A positive direct or indirect Coombs test may develop during treatment with imipenem/cilastatin.<br /><u>Antibacterial spectrum</u><br />The antibacterial spectrum of imipenem/cilastatin should be taken into account especially in lifethreatening<br />conditions before embarking on any empiric treatment. Furthermore, due to the<br />limited susceptibility of specific pathogens associated with e.g. bacterial skin and soft-tissue<br />infections, to imipenem/cilastatin, caution should be exercised. The use of imipenem/cilastatin is<br />not suitable for treatment of these types of infections unless the pathogen is already documented<br />and known to be susceptible or there is a very high suspicion that the most likely pathogen(s)<br />would be suitable for treatment. Concomitant use of an appropriate anti-MRSA agent may be<br />indicated when MRSA infections are suspected or proven to be involved in the approved<br />indications. Concomitant use of an aminoglycoside may be indicated when Pseudomonas<br />aeruginosa infections are suspected or proven to be involved in the approved indications (see<br />section 4.1).<br /><u>Interaction with valproic acid</u><br />The concomitant use of imipenem/cilastatin and valproic acid/sodium valproate is not<br />recommended (see section 4.5).<br /><u>Clostridium difficile</u><br />Antibiotic-associated colitis and pseudomembranous colitis have been reported with<br />imipenem/cilastatin and with nearly all other anti-bacterial agents and may range from mild to<br />life-threatening in severity. It is important to consider this diagnosis in patients who develop<br />diarrhoea during or after the use of imipenem/cilastatin (see section 4.8). Discontinuation of<br />therapy with imipenem/cilastatin and the administration of specific treatment for Clostridium<br />difficile should be considered. Medicinal products that inhibit peristalsis should not be given.<br /><u>Meningitis</u><br />&#39;IMESTA&#39; is not recommended for the therapy of meningitis.<br />Renal impairment<br />Imipenem-cilastatin accumulates in patients with reduced kidney function. CNS adverse<br />reactions may occur if the dose is not adjusted to the renal function, see section 4.2 and 4.4<br />&quot;Central nervous system&quot; in this section.<br /><u>Central nervous system</u><br />CNS adverse reactions such as myoclonic activity, confusional states, or seizures have been<br />reported, especially when recommended doses based on renal function and body weight were<br />exceeded. These experiences have been reported most commonly in patients with CNS disorders<br />(e.g. brain lesions or history of seizures) and/or compromised renal function in whom<br />accumulation of the administered entities could occur. Hence close adherence to recommended<br />dose schedules is urged especially in these patients (see section 4.2). Anticonvulsant therapy<br />should be continued in patients with a known seizure disorder.<br />Special awareness should be made to neurological symptoms or convulsions in children with<br />known risk factors for seizures, or on concomitant treatment with medicinal products lowering<br />the seizures threshold.<br />If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically and<br />placed on anticonvulsant therapy if not already instituted. If CNS symptoms continue, the dose<br />of &#39;IMESTA&#39; should be decreased or discontinued.<br />Patients with creatinine clearances of &le;5 ml/min/1.73 m2 should not receive &#39;IMESTA&#39;<br />unless haemodialysis is instituted within 48 hours. For patients on haemodialysis, &#39;IMESTA&#39; is<br />recommended only when the benefit outweighs the potential risk of seizures (see section 4.2).</p><p><u>Paediatric use</u><br />Clinical data are insufficient to recommend the use of &#39;IMESTA&#39; in children under 1 year of age<br />or paediatric patients with impaired renal function (serum creatinine &gt;2 mg/dl). See also above<br />under <u>Central nervous system.</u><br />&#39;IMESTA&#39; 500 mg/500 mg contains 37.6 mg of sodium (1.6 mEq) which should be taken into<br />consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Generalized seizures have been reported in patients who received ganciclovir and &#39;IMESTA&#39;.<br />These medicinal products should not be used concomitantly unless the potential benefit<br />outweighs the risks.<br />Decreases in valproic acid levels that may fall below the therapeutic range have been reported<br />when valproic acid was co-administered with carbapenem agents. The lowered valproic acid<br />levels can lead to inadequate seizure control; therefore, concomitant use of imipenem and<br />valproic acid/sodium valproate is not recommended and alternative antibacterial or anticonvulsant<br />therapies should be considered (see section 4.4).<br />Oral anti-coagulants<br />Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects.<br />There have been many reports of increases in the anti-coagulant effects of orally administered<br />anti-coagulant agents, including warfarin in patients who are concomitantly receiving<br />antibacterial agents. The risk may vary with the underlying infection, age and general status of<br />the patient so that the contribution of the antibiotic to the increase in INR (international<br />normalised ratio) is difficult to assess. It is recommended that the INR should be monitored<br />frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant<br />agent.<br />Concomitant administration of &#39;IMESTA&#39; and probenecid resulted in minimal increases in the<br />plasma levels and plasma half-life of imipenem. The urinary recovery of active (nonmetabolised)<br />imipenem decreased to approximately 60% of the dose when &#39;IMESTA&#39; was<br />administered with probenecid. Concomitant administration of &#39;IMESTA&#39; and probenecid doubled<br />the plasma level and half-life of cilastatin, but had no effect on urine recovery of cilastatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />There are no adequate and well-controlled studies for the use of imipenem/cilastatin in pregnant<br />women.<br />Studies in pregnant monkeys have shown reproductive toxicity (see section 5.3). The potential<br />risk for humans is unknown.<br />&#39;IMESTA&#39; should be used during pregnancy only if the potential benefit justifies the potential<br />risk to the foetus.<br /><u>Breast-feeding</u><br />Imipenem and cilastatin are excreted into the mother&#39;s milk in small quantities. Little absorption<br />of either compound occurs following oral administration. Therefore it is unlikely that the<br />suckling infant will be exposed to significant quantities. If the use of &#39;IMESTA&#39; is deemed<br />necessary, the benefit of breast feeding for the child should be weighed against the possible risk<br />for the child.<br /><u>Fertility</u><br />There are no data available regarding potential effects of imipenem/cilastatin treatment on male<br />or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.<br />However, there are some side effects (such as hallucination, dizziness, somnolence, and vertigo)<br />associated with this product that may affect some patients&#39; ability to drive or operate machinery<br />(see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials including 1,723 patients treated with imipenem/cilastatin intravenous the most<br />frequently reported systemic adverse reactions that were reported at least possibly related to<br />therapy were nausea (2.0%), diarrhoea (1.8%), vomiting (1.5%), rash (0.9%), fever (0.5%),<br />hypotension (0.4%), seizures (0.4%) (see section 4.4), dizziness (0.3%), pruritus (0.3%), urticaria<br />(0.2%), somnolence (0.2%). Similarly, the most frequently reported local adverse reactions were<br />phlebitis/thrombophlebitis (3.1%), pain at the injection site (0.7%), erythema at the injection site<br />(0.4%) and vein induration (0.2%). Increases in serum transaminases and in alkaline phosphatase<br />are also commonly reported.<br />The following adverse reactions have been reported in clinical studies or during post-marketing<br />experience.<br />All adverse reactions are listed under system organ class and frequency: Very common<br />(&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000<br />to &lt;1/1,000), Very rare (&lt;1/10,000) and not known (cannot be estimated from the<br />available data).<br />Within each frequency grouping, undesirable effects are presented in order of decreasing<br />seriousness.</p><table border="1" cellspacing="1" cellpadding="1" style="width:619px"><tbody><tr><td style="width:190px"><strong>System Organ Class</strong></td><td style="width:175px"><strong>Frequency</strong></td><td style="width:253px"><strong>Event</strong></td></tr><tr><td style="width:190px">Infections and infestations</td><td style="width:175px">Rare</td><td style="width:253px">pseudomembranous colitis, candidiasis</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Very rare</td><td style="width:253px">gastro-enteritis</td></tr><tr><td style="width:190px">Blood and lymphatic system<br />disorders</td><td style="width:175px">Common</td><td style="width:253px">eosinophilia</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Uncommon</td><td style="width:253px">pancytopenia, neutropenia, leucopenia,<br />thrombocytopenia, thrombocytosis</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Rare</td><td style="width:253px">agranulocytosis</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Very rare</td><td style="width:253px">haemolytic anaemia, bone marrow depression</td></tr><tr><td style="width:190px">Immune system disorders</td><td style="width:175px">Rare</td><td style="width:253px">anaphylactic reactions</td></tr><tr><td style="width:190px">Psychiatric disorders</td><td style="width:175px">Uncommon</td><td style="width:253px">psychic disturbances including hallucinations<br />and confusional states</td></tr><tr><td style="width:190px">Nervous system disorders</td><td style="width:175px">Uncommon</td><td style="width:253px">seizures, myoclonic activity, dizziness,<br />somnolence</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Rare</td><td style="width:253px">encephalopathy, paraesthesia, focal tremor, taste perversion</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Very rare</td><td style="width:253px">aggravation of myasthenia gravis, headache</td></tr><tr><td style="width:190px">Ear and labyrinth disorders</td><td style="width:175px">Rare</td><td style="width:253px">hearing loss</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Very rare</td><td style="width:253px">vertigo, tinnitus</td></tr><tr><td style="width:190px">Cardiac disorders</td><td style="width:175px">Very rare</td><td style="width:253px">cyanosis, tachycardia, palpitations</td></tr><tr><td style="width:190px">Vascular disorders</td><td style="width:175px">Common</td><td style="width:253px">thrombophlebitis</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Uncommon</td><td style="width:253px">hypotension</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Very rare</td><td style="width:253px">flushing</td></tr><tr><td style="width:190px">Respiratory, thoracic and<br />mediastinal disorders</td><td style="width:175px">Very rare</td><td style="width:253px">dyspnoea, hyperventilation, pharyngeal pain</td></tr><tr><td style="width:190px">Gastrointestinal disorders</td><td style="width:175px">Common</td><td style="width:253px">diarrhoea, vomiting, nausea<br />Medicinal product-related nausea and/or<br />vomiting appear to occur more frequently in<br />granulocytopenic patients than in nongranulocytopenic<br />patients treated with<br />&#39;IMESTA&#39;</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Rare</td><td style="width:253px">staining of teeth and/or tongue</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Very rare</td><td style="width:253px">haemorrhagic colitis, abdominal pain, heartburn,<br />glossitis, tongue papilla hypertrophy, increased salivation</td></tr><tr><td style="width:190px">Hepatobiliary disorders</td><td style="width:175px">Rare</td><td style="width:253px">hepatic failure, hepatitis</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Very Rare</td><td style="width:253px">fulminant hepatitis</td></tr><tr><td style="width:190px">Skin and subcutaneous tissue<br />disorders</td><td style="width:175px">Common</td><td style="width:253px">rash (e.g. exanthematous)</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Uncommon</td><td style="width:253px">urticaria, pruritus</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Rare</td><td style="width:253px">toxic epidermal necrolysis, angioedema,<br />Stevens-Johnson syndrome, erythema<br />multiforme, exfoliative dermatitis</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Very Rare</td><td style="width:253px">hyperhidrosis, skin texture changes</td></tr><tr><td style="width:190px">Musculoskeletal and connective<br />tissue disorders</td><td style="width:175px">Very Rare</td><td style="width:253px">polyarthralgia, thoracic spine pain</td></tr><tr><td style="width:190px">Renal and urinary disorders</td><td style="width:175px">Rare</td><td style="width:253px">acute renal failure, oligurial/anuria, polyuria,<br />urine discoloration (harmless and should not be<br />confused with haematuria)<br />The role of &#39;IMESTA&#39; in changes in renal<br />function is difficult to assess, since factors<br />predisposing to pre-renal azotemia or to<br />impaired renal function usually have been<br />present.</td></tr><tr><td style="width:190px">Reproductive system and breast<br />disorders</td><td style="width:175px">Very rare</td><td style="width:253px">pruritus vulvae</td></tr><tr><td style="width:190px">General disorders and<br />administration site conditions</td><td style="width:175px">Uncommon</td><td style="width:253px">fever, local pain and induration at the injection<br />site, erythema at the injection site</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Very rare</td><td style="width:253px">chest discomfort, asthenia/weakness</td></tr><tr><td style="width:190px">Investigations</td><td style="width:175px">Common</td><td style="width:253px">increases in serum transaminases, increases in&nbsp;serum alkaline phosphatase</td></tr><tr><td style="width:190px">&nbsp;</td><td style="width:175px">Uncommon</td><td style="width:253px">A positive direct Coombs&#39; test, prolonged<br />prothrombin time, decreased haemoglobin,<br />increases in serum bilirubin, elevations in serum<br />creatinine, elevations in blood urea nitrogen</td></tr></tbody></table><p>Paediatric (&ge;3 months of age)<br />In studies of 178 paediatric patients &ge;3 months of age, the reported adverse reactions<br />were consistent with those reported for adults.</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><strong>To report any side effect(s):</strong><br /> The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdose that can occur are consistent with the adverse reaction profile; these may<br />include seizures, confusion, tremors, nausea, vomiting, hypotension, bradycardia. No specific<br />information is available on treatment of overdose with &#39;IMESTA&#39;. Imipenem-cilastatin sodium is<br />haemodialyzable. However, usefulness of this procedure in the overdose setting is unknown.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, carbapenems, ATC code: J01D H51<br /><u>Mode of action</u><br />&#39;IMESTA&#39; consists of two components: imipenem and cilastatin sodium in a 1:1 ratio by weight.<br />Imipenem, also referred to as N-formimidoyl-thienamycin, is a semi-synthetic derivative of<br />thienamycin, the parent compound produced by the filamentous bacterium Streptomyces<br />cattleya.<br />Imipenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Grampositive<br />and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).<br />Cilastatin sodium is a competitive, reversible and specific inhibitor of dehydropeptidase-I, the<br />renal enzyme which metabolizes and inactivates imipenem. It is devoid of intrinsic antibacterial<br />activity and does not affect the antibacterial activity of imipenem.<br />Pharmacokinetic/Pharmacodynamic (PK/PD) relationship<br />Similar to other beta-lactam antibacterial agents, the time that imipenem concentrations exceed<br />the MIC (T&gt;MIC) has been shown to best correlate with efficacy.<br />Mechanism of resistance<br />Resistance to imipenem may be due to the following:<br />&bull; Decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished<br />production of porins)<br />&bull; Imipenem may be actively removed from the cell with an efflux pump.</p><p>&bull; Reduced affinity of PBPs to imipenem<br />&bull; Imipenem is stable to hydrolysis by most beta-lactamases, including penicillinases and<br />cephalosporinases produced by gram-positive and gram-negative bacteria, with the exception of<br />relatively rare carbapenem hydrolysing beta-lactamases. Species resistant to other carbapenems<br />do generally express co-resistance to imipenem. There is no target-based cross-resistance<br />between imipenem and agents of the quinolone, aminoglycoside, macrolide and tetracycline<br />classes.<br /><u>Breakpoints</u><br />EUCAST MIC breakpoints for imipenem to separate susceptible (S) pathogens from resistant (R)<br />pathogens are as follows (v 1,1 2010-04-27):<br />&bull; Enterobacteriaceae 1: S &le;2 mg/l, R &gt;8 mg/l<br />&bull; Pseudomonas spp. 2: S &le;4 mg/l, R &gt;8 mg/l<br />&bull; Acinetobacter spp.: S &le;2 mg/l, R &gt;8 mg/l<br />&bull; Staphylococcus spp. 3: Inferred from cefoxitin susceptibility<br />&bull; Enterococcus spp.: S &le;4 mg/l, R &gt;8 mg/l<br />&bull; Streptococcus A, B, C, G: The beta-lactam susceptibility of betahaemolytic<br />streptococcus groups A, B, C and G is inferred from the penicillin susceptibility.<br />&bull; Streptococcus pneumoniae 4: S &le;2 mg/l, R &gt;2 mg/l<br />&bull; Other streptococci 4: S &le;2 mg/l, R &gt;2 mg/l<br />&bull; Haemophilus influenzae 4: S &le;2 mg/l, R &gt;2 mg/l<br />&bull; Moraxalla catarrhalis 4: S &le;2 mg/l, R &gt;2 mg/l<br />&bull; Neisseria gonorrhoeae: There is insufficient evidence that Neisseria gonorrhoeae is a good<br />target for therapy with imipenem.<br />&bull; Gram-positive anaerobes: S &le;2 mg/l, R &gt;8 mg/l<br />&bull; Gram-negative anaerobes: S &le;2 mg/l, R &gt;8 mg/l<br />&bull; Non-species related breakpoints 5: S &le;2 mg/l, R &gt;8 mg/l<br />1 Proteus and Morganella species are considered poor targets for imipenem.<br />2 The breakpoints for Pseudomonas relate to high dose frequent therapy (1g every 6 hours).<br />3 Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.<br />4 Strains with MIC values above the susceptible breakpoint are very rare or not yet reported. The<br />identification and antimicrobial susceptibility tests on any such isolate must be repeated and if<br />the result is confirmed the isolate must be sent to a reference laboratory. Until there is evidence<br />regarding clinical response for confirmed isolates with MIC above the current resistant<br />breakpoint they should be reported resistant.<br />5 Non-species related breakpoint have been determined mainly on the basis of PK/PD data and<br />are independent of MIC distributions of specific species. They are for use only for species not<br />mentioned in the overview of species-related breakpoints or footnotes.<br /><u>Susceptibility</u><br />The prevalence of acquired resistance may vary geographically and with time for selected<br />species and local information on resistance is desirable, particularly when treating severe<br />infections. As necessary, expert advice should be sought when the local prevalence of resistance<br />is such that the utility of the agent in at least some types of infections is questionable.</p><p><strong>Commonly susceptible species:<br />Gram-positive aerobes:</strong><br /><em>Enterococcus faecalis<br />Staphylococcus aureus (Methicillin-susceptible)*<br />Staphylococcus coagulase negative (Methicillin-susceptible)<br />Streptococcus agalactiae<br />Streptococcus pneumoniae<br />Streptococcus pyogenes<br />Streptococcus viridans group</em><br /><strong>Gram-negative aerobes:</strong><br /><em>Citrobacter freundii<br />Enterobacter aerogenes<br />Enterobacter cloacae<br />Escherichia coli<br />Haemophilus influenzae<br />Klebsiella oxytoca<br />Klebsiella pneumoniae<br />Moraxella catarrhalis<br />Serratia marcescens</em><br /><strong>Gram-positive anaerobes:</strong><br /><em>Clostridium perfringens**<br />Peptostreptococcus spp.**</em><br /><strong>Gram-negative anaerobes:</strong><br /><em>Bacteroides fragilis<br />Bacteroides fragilis group<br />Fusobacterium spp.<br />Porphyromonas asaccharolytica<br />Prevotella spp.<br />Veillonella spp.</em><br /><strong>Species for which acquired resistance may be a problem:<br />Gram-negative aerobes:</strong><br /><em>Acinetobacter baumannii<br />Pseudomonas aeruginosa</em><br /><strong>Inherently resistant species:<br />Gram positive aerobes:</strong><br /><em>Enterococcus faecium</em></p><p><strong>Gram negative aerobes:</strong><br /><em>Some strains of Burkholderia cepacia (formerly Pseudomonas cepacia)<br />Legionella spp.<br />Stenotrophomonas maltophilia (formerly Xanthomonas maltophilia, formerly Pseudomonas<br />maltophilia)</em><br /><strong>Others:</strong><br /><em>Chlamydia spp.<br />Chlamydophila spp.<br />Mycoplasma spp.<br />Ureoplasma urealyticum</em></p><p>*All methicillin-resistant staphylococci are resistant to imipenem/cilastatin.<br />** EUCAST non-species related breakpoint is used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Imipenem</u><br /><em>Plasma concentrations</em><br />In normal volunteers, intravenous infusion of &#39;IMESTA&#39; over 20 minutes resulted in peak plasma<br />levels of imipenem ranging from 12 to 20 &mu;g/ml for the 250 mg/250 mg dose, from 21 to 58<br />&mu;g/ml for the 500 mg/500 mg dose, and from 41 to 83 &mu;g/ml for the 1000 mg/1000 mg dose. The<br />mean peak plasma levels of imipenem following the 250 mg/250 mg, 500 mg/500 mg, and 1000<br />mg /1000 mg doses were 17, 39, and 66 &mu;g/ml, respectively. At these doses, plasma levels of<br />imipenem decline to below 1 &mu;g/ml or less in four to six hours.<br /><em>Distribution</em><br />The binding of imipenem to human serum proteins is approximately 20%.<br /><em>Biotransformation and elimination</em><br />When administered alone, imipenem is metabolised in the kidneys by dehydropeptidase-I.<br />Individual urinary recoveries ranged from 5 to 40%, with an average recovery of 15-20% in<br />several studies.<br />Cilastatin is a specific inhibitor of dehydropeptidase-I enzyme and effectively inhibits<br />metabolism of imipenem so that concomitant administration of imipenem and cilastatin allows<br />therapeutic antibacterial levels of imipenem to be attained in both urine and plasma.<br />The plasma half-life of imipenem was one hour. Approximately 70% of the administered<br />antibiotic was recovered intact in the urine within ten hours, and no further urinary excretion of<br />imipenem was detectable. Urine concentrations of imipenem exceeded 10 &mu;g/ml for up to eight<br />hours after a 500 mg/500 mg dose of &#39;IMESTA&#39;. The remainder of the administered dose was<br />recovered in the urine as antibacterially inactive metabolites, and faecal elimination of imipenem<br />was essentially nil.<br />No accumulation of imipenem in plasma or urine has been observed with regimens of &#39;IMESTA&#39;,<br />administered as frequently as every six hours, in patients with normal renal function.<br /><u>Cilastatin</u><br /><em>Plasma concentrations</em><br />Peak plasma levels of cilastatin, following a 20 minute intravenous infusion of &#39;IMESTA&#39;, ranged<br />from 21 to 26 &mu;g/ml for the 250 mg/250 mg dose, from 21 to 55 &mu;g/ml for the 500 mg/500 mg<br />dose and from 56 to 88 &mu;g/ml for the 1000 mg/1000 mg dose. The mean peak plasma levels of</p><p>cilastatin following the 250 mg/250 mg, 500 mg/500 mg, and 1000 mg/1000 mg doses were 22,<br />42, and 72 &mu;g/ml respectively.<br /><em>Distribution</em><br />The binding of cilastatin to human serum proteins is approximately 40%.<br /><em>Biotransformation and elimination</em><br />The plasma half-life of cilastatin is approximately one hour. Approximately 70-80% of the dose<br />of cilastatin was recovered unchanged in the urine as cilastatin within 10 hours of administration<br />of &#39;IMESTA&#39;. No further cilastatin appeared in the urine thereafter. Approximately 10% was<br />found as the N-acetyl metabolite, which has inhibitory activity against dehydropeptidase<br />comparable to that of cilastatin. Activity of dehydropeptidase-I in the kidney returned to normal<br />levels shortly after the elimination of cilastatin from the blood stream.<br /><u>Renal insufficiency</u><br />Following a single 250 mg/250 mg intravenous dose of &#39;IMESTA&#39;, the area under the curve<br />(AUCs) for imipenem increased 1.1-fold, 1.9-fold, and 2.7-fold in subjects with mild (Creatinine<br />Clearance (CrCL) 50-80 ml/min/1.73 m2), moderate (CrCL 30-&lt;50 ml/min/1.73 m2), and severe<br />(CrCL &lt;30 ml/min/1.73 m2) renal impairment, respectively, compared to subjects with normal<br />renal function (CrCL &gt;80 ml/min/1.73 m2), and AUCs for cilastatin increased 1.6-fold, 2.0-fold,<br />and 6.2-fold in subjects with mild, moderate, and severe renal impairment, respectively,<br />compared to subjects with normal renal function. Following a single 250 mg/250 mg intravenous<br />dose of &#39;IMESTA&#39; given 24 hours after haemodialysis, AUCs for imipenem and cilastatin were<br />3.7-fold and 16.4-fold higher, respectively, as compared to subjects with normal renal function.<br />Urinary recovery, renal clearance and plasma clearance of imipenem and cilastatin decrease with<br />decreasing renal function following intravenous administration of &#39;IMESTA&#39;. Dose adjustment is<br />necessary for patients with impaired renal function (see section 4.2).<br /><u>Hepatic insufficiency</u><br />The pharmacokinetics of imipenem in patients with hepatic insufficiency have not been<br />established. Due to the limited extent of hepatic metabolism of imipenem, its pharmacokinetics<br />are not expected to be affected by hepatic impairment. Therefore, no dose adjustment is<br />recommended in patients with hepatic impairment (see section 4.2).<br /><u>Paediatric patients</u><br />The average clearance (CL) and volume of distribution (Vdss) for imipenem were approximately<br />45% higher in paediatric patients (3 months to 14 years) as compared to adults. The AUC for<br />imipenem following administration of 15/15 mg/kg per body weight of imipenem/cilastatin to<br />paediatric patients was approximately 30% higher than the exposure in adults receiving a 500<br />mg/500 mg dose. At the higher dose, the exposure following administration of 25/25 mg/kg<br />imipenem/cilastatin to children was 9% higher as compared to the exposure in adults receiving a<br />1000 mg/1000 mg dose.<br /><u>Elderly</u><br />In healthy elderly volunteers (65 to 75 years of age with normal renal function for their age), the<br />pharmacokinetics of a single dose of &#39;IMESTA&#39; 500 mg/500 mg administered intravenously over<br />20 minutes were consistent with those expected in subjects with slight renal impairment for<br />which no dose alteration is considered necessary. The mean plasma half-lives of imipenem and<br />cilastatin were 91 &plusmn; 7.0 minutes and 69 &plusmn; 15 minutes, respectively. Multiple dosing has no effect<br />on the pharmacokinetics of either imipenem or cilastatin, and no accumulation of<br />imipenem/cilastatin was observed (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on repeated dose toxicity and<br />genotoxicity studies.<br />Animal studies showed that the toxicity produced by imipenem, as a single entity, was limited to<br />the kidney. Co-administration of cilastatin with imipenem in a 1:1 ratio prevented the<br />nephrotoxic effects of imipenem in rabbits and monkeys. Available evidence suggests that<br />cilastatin prevents the nephrotoxicity by preventing entry of imipenem into the tubular cells.<br />A teratology study in pregnant cynomolgus monkeys given imipenem-cilastatin sodium at doses<br />of 40/40 mg/kg/day (bolus intravenous injection) resulted in maternal toxicity including emesis,<br />inappetence, body weight loss, diarrhoea, abortion, and death in some cases. When doses of<br />imipenem-cilastatin sodium (approximately 100/100 mg/kg/day or approximately 3 times the<br />usual recommended daily human intravenous dose) were administered to pregnant cynomolgus<br />monkeys at an intravenous infusion rate which mimics human clinical use, there was minimal<br />maternal intolerance (occasional emesis), no maternal deaths, no evidence of teratogenicity, but<br />an increase in embryonic loss relative to control groups (see section 4.6).<br />Long term studies in animals have not been performed to evaluate carcinogenic potential of<br />imipenem-cilastatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium bicarbonate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is chemically incompatible with lactate and should not be reconstituted in<br />diluents containing lactate. However, it can be administered into an I.V. system through which a<br />lactate solution is being infused.<br />This medicinal product must not be mixed with other medicinal products except those mentioned<br />in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
After reconstitution:
Diluted solutions should be used immediately. The time interval between the beginning of
reconstitution and the end of intravenous infusion should not exceed two hours at 30 °C.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.<br />Do not freeze the reconstituted solution.<br />For storage conditions of the reconstituted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20 ml Type III glass vials.<br />The medicinal product is supplied in packs of 1 vial, 10 vials and 25 vials.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each vial is for single use only.<br />Reconstitution:<br />Contents of each vial must be transferred to 100 ml of an appropriate infusion solution (see<br />section 6.2 and 6.3): 0.9% sodium chloride. In exceptional circumstances where 0.9% sodium<br />chloride cannot be used for clinical reasons 5% glucose may be used instead.<br />A suggested procedure is to add approximately 10 ml of the appropriate infusion solution to the<br />vial. Shake well and transfer the resulting mixture to the infusion solution container.</p><p>CAUTION: THE MIXTURE IS NOT FOR DIRECT INFUSION.<br />Repeat with an additional 10 ml of infusion solution to ensure complete transfer of vial contents<br />to the infusion solution. The resulting mixture should be agitated until clear.<br />The concentration of the reconstituted solution following the above procedure is approximately 5<br />mg/ml for both imipenem and cilastatin.<br />Variations of colour, from colourless to yellow, do not affect the potency of the product.<br />Any unused product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufatured by:
ACS DOBFAR S.P.A
For
SPIMACO
Saudi Pharmaceutical Industries &
Medical Appliance Corporation
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>